in 1987, amylin pharmaceuticals was co-founded by howard e. greene jr., former ceo of san diego biotech pioneer hybridtech, to develop a treatment for diabetes from a synthetic analog of amylin. amylin was discovered by researchers at oxford university earlier that year. greene served as ceo from 1987 to 1996. amylin completed its ipo in 1992.